The right chance for temozolomide in metastatic colorectal cancer?

necessary but not sufficient condition for achieving with TMZ the magnitude of benefit expected by a tailored use of this drug. The current trial of Morano et al., with the boost of irinotecan re-introduction, leveraged this strategy to enhanced results. Whether this might represent a plateau of efficacy will be determined through more preclinical work and further improvement in molecular selection.

[1]  G. Pruneri,et al.  Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  A. Bardelli,et al.  Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  E. Valtorta,et al.  Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience , 2017, Targeted Oncology.

[4]  T. Cenci,et al.  A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation , 2017, British Journal of Cancer.

[5]  J. Guinney,et al.  Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer , 2017, Nature Reviews Cancer.

[6]  A. Bardelli,et al.  Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. , 2017, European journal of cancer.

[7]  M. Esteller,et al.  Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  F. D. De Braud,et al.  Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer , 2016, Targeted Oncology.

[9]  M. Gariboldi,et al.  Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  M. Esteller,et al.  Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer , 2013, Clinical Cancer Research.

[11]  J. Tabernero,et al.  Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials , 2012, Molecular Cancer Therapeutics.

[12]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. , 2000, Cancer research.

[13]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.